Tetsuo Ashizawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Tetsuo Ashizawa has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Adam Rosenblatt
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
2 shared publications - Alexandra Durr
INSERM U679, Hôpital de la Salpêtrière, Paris, France
2 shared publications - Alice Lazzarini
Department of Neurology, Robert Wood Johnson school of Medicine and Dentistry of New Jersey, USA
2 shared publications - Andrea Novelletto
University of Rome Tor Vergata
2 shared publications - Andrea Zanko
Division of Medical Genetics, UCSF, San Francisco, USA
2 shared publications - Anthony J Lechich
Department of Neurology, Columbia College of Physicians, New York, USA
2 shared publications
Latest Publications
- Open Access
- 17 August 2006
- Published by Springer Nature in BMC Medical Genetics
- Vol. 7 (1) , 1-8
Genome-wide significance for a modifier of age at neurological onset in Huntington's Disease at 6q23-24: the HD MAPS study
Background: Age at onset of Huntington's disease (HD) is correlated with the size of the abnormal CAG repeat expansion in the HD gene; however, several studies have indicated that other genetic factors also contribute to the variability in HD age at onset. To identify modifier genes, we recently reported a whole-genome scan in a sample of 629 affected sibling pairs from 295 pedigrees, in which six genomic regions provided suggestive evidence for quantitative trait loci (QTL), modifying age at onset in HD. Methods: In order to test the replication of this finding, eighteen microsatellite markers, three from each of the six genomic regions, were genotyped in 102 newly recruited sibling pairs from 69 pedigrees, and data were analyzed, using a multipoint linkage variance component method, in the follow-up sample and the combined sample of 352 pedigrees with 753 sibling pairs. Results: Suggestive evidence for linkage at 6q23-24 in the follow-up sample (LOD = 1.87, p = 0.002) increased to genome-wide significance for linkage in the combined sample (LOD = 4.05, p = 0.00001), while suggestive evidence for linkage was observed at 18q22, in both the follow-up sample (LOD = 0.79, p = 0.03) and the combined sample (LOD = 1.78, p = 0.002). Epistatic analysis indicated that there is no interaction between 6q23-24 and other loci. Conclusion: In this replication study, linkage for modifier of age at onset in HD was confirmed at 6q23-24. Evidence for linkage was also found at 18q22. The demonstration of statistically significant linkage to a potential modifier locus opens the path to location cloning of a gene capable of altering HD pathogenesis, which could provide a validated target for therapeutic development in the human patient.
- 17 August 2006
- Published by Springer Nature in BMC Medical Genetics
- Vol. 7 (1) , 1-8
Open AccessGenome-wide significance for a modifier of age at neurological onset in Huntington's Disease at 6q23-24: the HD MAPS study
Background: Age at onset of Huntington's disease (HD) is correlated with the size of the abnormal CAG repeat expansion in the HD gene; however, several studies have indicated that other genetic factors also contribute to the variability in HD age at onset. To identify modifier genes, we recently reported a whole-genome scan in a sample of 629 affected sibling pairs from 295 pedigrees, in which six genomic regions provided suggestive evidence for quantitative trait loci (QTL), modifying age at onset in HD. Methods: In order to test the replication of this finding, eighteen microsatellite markers, three from each of the six genomic regions, were genotyped in 102 newly recruited sibling pairs from 69 pedigrees, and data were analyzed, using a multipoint linkage variance component method, in the follow-up sample and the combined sample of 352 pedigrees with 753 sibling pairs. Results: Suggestive evidence for linkage at 6q23-24 in the follow-up sample (LOD = 1.87, p = 0.002) increased to genome-wide significance for linkage in the combined sample (LOD = 4.05, p = 0.00001), while suggestive evidence for linkage was observed at 18q22, in both the follow-up sample (LOD = 0.79, p = 0.03) and the combined sample (LOD = 1.78, p = 0.002). Epistatic analysis indicated that there is no interaction between 6q23-24 and other loci. Conclusion: In this replication study, linkage for modifier of age at onset in HD was confirmed at 6q23-24. Evidence for linkage was also found at 18q22. The demonstration of statistically significant linkage to a potential modifier locus opens the path to location cloning of a gene capable of altering HD pathogenesis, which could provide a validated target for therapeutic development in the human patient.
- 19 August 2002
- Published by Wiley in Annals of Neurology
- Vol. 52 (4) , 435-441
Instability of a premutation allele in homozygous patients with myotonic dystrophy type 1
Myotonic dystrophy type 1 (DM1) is caused by the expansion of an unstable CTG repeat in the DMPK gene on chromosome 19q13.3. We present two siblings with DM1 who each inherited a premutation allele, (CTG)43, stably transmitted from the mother and a full‐mutation allele, either (CTG)500 or (CTG)180, derived from a paternal protomutation allele, (CTG)52. Small‐pool polymerase chain reaction analysis showed that the (CTG)52 repeat allele was relatively stable in somatic tissues but was highly unstable in the male germline and extremely biased toward further expansion, consistent with the high levels of anticipation observed in DM1 families. The (CTG)43 allele showed subtle somatic instability in the mother, with maximum additions of two repeats and deletions of one repeat. Conversely, in the younger affected siblings the (CTG)43 allele showed a high degree of somatic instability (approximately 70% mutation load), resulting in deletions reverting to the high end of the normal range (down to [CTG]33) and additions up to the proto‐mutation range (up to [CTG]64). The difference in the somatic stability of the (CTG)43 allele between the mother and her offspring suggests that interallelic interactions or other mechanisms in trans regulate the stability of the (CTG)43 premutation allele.
- 19 August 2002
- Published by Wiley in Annals of Neurology
- Vol. 52 (4) , 435-441
Instability of a premutation allele in homozygous patients with myotonic dystrophy type 1
Myotonic dystrophy type 1 (DM1) is caused by the expansion of an unstable CTG repeat in the DMPK gene on chromosome 19q13.3. We present two siblings with DM1 who each inherited a premutation allele, (CTG)43, stably transmitted from the mother and a full‐mutation allele, either (CTG)500 or (CTG)180, derived from a paternal protomutation allele, (CTG)52. Small‐pool polymerase chain reaction analysis showed that the (CTG)52 repeat allele was relatively stable in somatic tissues but was highly unstable in the male germline and extremely biased toward further expansion, consistent with the high levels of anticipation observed in DM1 families. The (CTG)43 allele showed subtle somatic instability in the mother, with maximum additions of two repeats and deletions of one repeat. Conversely, in the younger affected siblings the (CTG)43 allele showed a high degree of somatic instability (approximately 70% mutation load), resulting in deletions reverting to the high end of the normal range (down to [CTG]33) and additions up to the proto‐mutation range (up to [CTG]64). The difference in the somatic stability of the (CTG)43 allele between the mother and her offspring suggests that interallelic interactions or other mechanisms in trans regulate the stability of the (CTG)43 premutation allele.
- Open Access
- 1 August 2002
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 59 (8) , 1285-1290
Clinical Features and ATTCT Repeat Expansion in Spinocerebellar Ataxia Type 10
THE SPINOCEREBELLAR ataxias (SCAs) are a genetically heterogeneous group of neurodegenerative disorders.1 Traditionally, the autosomal dominant cerebellar ataxias (ADCAs) have been classified according to phenotype. In the classification proposed by Harding,2 the ADCAs are divided into 3 different groups (ADCA I, II, and III) depending on the presence or absence of associated features, such as retinopathy or other extracerebellar signs. However, there are significant phenotypic overlaps and variability among these disorders, making a definitive clinical diagnosis difficult. Recent advances in the molecular genetics of these disorders have led to a genotypic classification using the SCA prefix.3 They are an expanding group of disorders, and 15 different loci (SCA1-8, SCA10-14, and SCA16-17) have been genetically mapped.1,3-8 In 6 of the disorders (SCA1-3, SCA6-7, and SCA17), the disease-producing mutation is an expansion involving the trinucleotide repeat CAG in the coding portion of the gene. In 2 of the disorders (SCA8 and SCA12), the reported mutations are in the noncoding portions of the disease genes.1 However, in SCA8, unlike SCA12, the expanded trinucleotide repeat involves a CTG rather than a CAG expansion.
- 1 August 2002
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 59 (8) , 1285-1290
Open AccessClinical Features and ATTCT Repeat Expansion in Spinocerebellar Ataxia Type 10
THE SPINOCEREBELLAR ataxias (SCAs) are a genetically heterogeneous group of neurodegenerative disorders.1 Traditionally, the autosomal dominant cerebellar ataxias (ADCAs) have been classified according to phenotype. In the classification proposed by Harding,2 the ADCAs are divided into 3 different groups (ADCA I, II, and III) depending on the presence or absence of associated features, such as retinopathy or other extracerebellar signs. However, there are significant phenotypic overlaps and variability among these disorders, making a definitive clinical diagnosis difficult. Recent advances in the molecular genetics of these disorders have led to a genotypic classification using the SCA prefix.3 They are an expanding group of disorders, and 15 different loci (SCA1-8, SCA10-14, and SCA16-17) have been genetically mapped.1,3-8 In 6 of the disorders (SCA1-3, SCA6-7, and SCA17), the disease-producing mutation is an expansion involving the trinucleotide repeat CAG in the coding portion of the gene. In 2 of the disorders (SCA8 and SCA12), the reported mutations are in the noncoding portions of the disease genes.1 However, in SCA8, unlike SCA12, the expanded trinucleotide repeat involves a CTG rather than a CAG expansion.
- 1 April 2002
- Published by Springer Nature in The Cerebellum
- Vol. 1 (2) , 143-158
A symposium of the Society for Experimental Neuropathology under the auspices of the American Neurological Association
- 1 April 2002
- Published by Springer Nature in The Cerebellum
- Vol. 1 (2) , 143-158
A symposium of the Society for Experimental Neuropathology under the auspices of the American Neurological Association
- 9 May 2001
- Published by Elsevier in Neuroscience Letters
- Vol. 305 (1) , 70-72
Alcohol dehydrogenase polymorphism and Parkinson's disease
- 9 May 2001
- Published by Elsevier in Neuroscience Letters
- Vol. 305 (1) , 70-72
Alcohol dehydrogenase polymorphism and Parkinson's disease
- Open Access
- 1 April 2001
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 10 (8) , 855-863
'Mitotic drive' of expanded CTG repeats in myotonic dystrophy type 1 (DM1)
In myotonic dystrophy type 1 (DM1), an expanded CTG repeat shows repeat size instability in somatic and germ line tissues with a strong bias toward further expansion. To investigate the mechanism of this expansion bias, 29 DM1 and six normal lymphoblastoid cell lines (LBCLs) were single-cell cloned from blood cells of 18 DM1 patients and six normal subjects. In all 29 cell lines, the expanded CTG repeat alleles gradually shifted toward further expansion by ‘step-wise’ mutations. Of these 29 cell lines, eight yielded a rapidly proliferating mutant with a gain of large repeat size that became the major allele population, eventually replacing the progenitor allele population. By mixing cell lines with different repeat expansions, we found that cells with larger CTG repeat expansion had a growth advantage over those with smaller expansions in culture. This growth advantage was attributable to increased cell proliferation mediated by Erk1,2 activation, which is negatively regulated by p21WAF1. This phenomenon, which we designated ‘mitotic drive’, is a novel mechanism which can explain the expansion bias of DM1 CTG repeat instability at the tissue level, on a basis independent of the DNA-based expansion models. The lifespans of the DM1 LBCLs were significantly shorter than normal cell lines. Thus, we propose a hypothesis that DM1 LBCLs drive themselves to extinction through a process related to increased proliferation.
- 1 April 2001
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 10 (8) , 855-863
Open Access'Mitotic drive' of expanded CTG repeats in myotonic dystrophy type 1 (DM1)
In myotonic dystrophy type 1 (DM1), an expanded CTG repeat shows repeat size instability in somatic and germ line tissues with a strong bias toward further expansion. To investigate the mechanism of this expansion bias, 29 DM1 and six normal lymphoblastoid cell lines (LBCLs) were single-cell cloned from blood cells of 18 DM1 patients and six normal subjects. In all 29 cell lines, the expanded CTG repeat alleles gradually shifted toward further expansion by ‘step-wise’ mutations. Of these 29 cell lines, eight yielded a rapidly proliferating mutant with a gain of large repeat size that became the major allele population, eventually replacing the progenitor allele population. By mixing cell lines with different repeat expansions, we found that cells with larger CTG repeat expansion had a growth advantage over those with smaller expansions in culture. This growth advantage was attributable to increased cell proliferation mediated by Erk1,2 activation, which is negatively regulated by p21WAF1. This phenomenon, which we designated ‘mitotic drive’, is a novel mechanism which can explain the expansion bias of DM1 CTG repeat instability at the tissue level, on a basis independent of the DNA-based expansion models. The lifespans of the DM1 LBCLs were significantly shorter than normal cell lines. Thus, we propose a hypothesis that DM1 LBCLs drive themselves to extinction through a process related to increased proliferation.
- Open Access
- 1 February 2001
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 58 (2) , 191-195
Genetic Testing in Spinocerebellar Ataxias
Although genetic tests for known spinocerebellar ataxia (SCA) genes are increasingly available, their exact clinical role has received much less attention. Currently available DNA tests can define the genotypes of up to two thirds of patients with dominantly inherited SCAs. Certain characteristic clinical features and ethnic predilection of some of the SCA subtypes may help prioritize specific SCA gene testing. Available data on genotype-phenotype correlation suggest that currently available DNA tests cannot accurately predict age of onset or prognosis. Because of the mostly adult-onset symptoms and the absence of effective treatment, genetic counseling is essential for addressing ethical, social, legal, and psychological issues associated with SCA DNA testing.
- 1 February 2001
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 58 (2) , 191-195
Open AccessGenetic Testing in Spinocerebellar Ataxias
Although genetic tests for known spinocerebellar ataxia (SCA) genes are increasingly available, their exact clinical role has received much less attention. Currently available DNA tests can define the genotypes of up to two thirds of patients with dominantly inherited SCAs. Certain characteristic clinical features and ethnic predilection of some of the SCA subtypes may help prioritize specific SCA gene testing. Available data on genotype-phenotype correlation suggest that currently available DNA tests cannot accurately predict age of onset or prognosis. Because of the mostly adult-onset symptoms and the absence of effective treatment, genetic counseling is essential for addressing ethical, social, legal, and psychological issues associated with SCA DNA testing.
- Open Access
- 1 December 1998
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 55 (12) , 1521-1523
The G209A Mutation in the α-Synuclein Gene Is Not Detected in Familial Cases of Parkinson Disease in Non-Greek and/or Italian Populations
PARKINSON DISEASE (PD) is one of the most common neurodegenerative disorders, characterized by bradykinesia, cogwheel rigidity, rest tremor, and impaired postural reflexes.1,2 Degeneration of dopaminergic neurons in the central nervous system and the presence of Lewy body cytoplasmic inclusions, particularly in substantia nigra, is the pathological hallmark of PD, but the cause of this selective neuronal degeneration remains unknown.1,2 Although an encephalitis virus (von Economo) and toxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) have caused clinical and pathological syndromes similar to PD in a small portion of cases, efforts to identify causative environmental factors in PD have been unsuccessful in most patients.1,2 Oxidative stress involving local iron accumulation, reduced glutathione levels, and mitochondrial dysfunction may play a role in the neuronal loss of PD, but it is not known whether these mechanisms are pathogenic events in PD.1
- 1 December 1998
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 55 (12) , 1521-1523
Open AccessThe G209A Mutation in the α-Synuclein Gene Is Not Detected in Familial Cases of Parkinson Disease in Non-Greek and/or Italian Populations
PARKINSON DISEASE (PD) is one of the most common neurodegenerative disorders, characterized by bradykinesia, cogwheel rigidity, rest tremor, and impaired postural reflexes.1,2 Degeneration of dopaminergic neurons in the central nervous system and the presence of Lewy body cytoplasmic inclusions, particularly in substantia nigra, is the pathological hallmark of PD, but the cause of this selective neuronal degeneration remains unknown.1,2 Although an encephalitis virus (von Economo) and toxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) have caused clinical and pathological syndromes similar to PD in a small portion of cases, efforts to identify causative environmental factors in PD have been unsuccessful in most patients.1,2 Oxidative stress involving local iron accumulation, reduced glutathione levels, and mitochondrial dysfunction may play a role in the neuronal loss of PD, but it is not known whether these mechanisms are pathogenic events in PD.1
- 1 January 1996
- Published by Springer Nature in Journal of Neurology
- Vol. 243 (10) , 715-721
Myotonic dystrophy phenotype without expansion of (CTG)n repeat: An entity distinct from proximal myotonic myopathy (PROMM)?
Myotonic dystrophy (DM) is associated with an expansion of an unstable (CTG)n repeat in the 3' untranslated region of the DM protein kinase (DMPK) gene on chromosome 19q13.3. We studied six patients from two families who showed no expansions of the repeat, in spite of their clinical diagnosis of DM. These patients had multi-systemic manifestations that were distinguishable from those seen in other myotonic disorders, including proximal myotonic myopathy (PROMM). In one additional family, two symptomatic members showed no expanded (CTG)n repeats, while their affected relatives had the expanded repeats. DM haplotype analysis failed to exclude the DMPK locus as a possible site of mutation in each family; however,DMPK mRNA levels were normal. We conclude that a mutation(s) other than the expanded (CTG)n repeat can cause the DM phenotype. The mutation(s) in these families remain(s) to be mapped and characterized.
- 1 January 1996
- Published by Springer Nature in Journal of Neurology
- Vol. 243 (10) , 715-721
Myotonic dystrophy phenotype without expansion of (CTG)n repeat: An entity distinct from proximal myotonic myopathy (PROMM)?
Myotonic dystrophy (DM) is associated with an expansion of an unstable (CTG)n repeat in the 3' untranslated region of the DM protein kinase (DMPK) gene on chromosome 19q13.3. We studied six patients from two families who showed no expansions of the repeat, in spite of their clinical diagnosis of DM. These patients had multi-systemic manifestations that were distinguishable from those seen in other myotonic disorders, including proximal myotonic myopathy (PROMM). In one additional family, two symptomatic members showed no expanded (CTG)n repeats, while their affected relatives had the expanded repeats. DM haplotype analysis failed to exclude the DMPK locus as a possible site of mutation in each family; however,DMPK mRNA levels were normal. We conclude that a mutation(s) other than the expanded (CTG)n repeat can cause the DM phenotype. The mutation(s) in these families remain(s) to be mapped and characterized.